Načítá se...
Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy
Combination cancer therapies aim to improve the probability and magnitude of therapeutic responses and reduce the likelihood of acquired resistance in an individual patient. However, drugs are tested in clinical trials on genetically diverse patient populations. We show here that patient-to-patient...
Uloženo v:
| Vydáno v: | Cell |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5741091/ https://ncbi.nlm.nih.gov/pubmed/29245013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2017.11.009 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|